PURPOSE: Insomnia in cancer patients is a common symptom contributing to poor quality of life and poor functioning. Sleep disturbances have been associated with inflammatory activity, and systemic cancer therapies chemotherapy, hormonal therapy, and immunotherapy may cause insomnia. We have carried out a meta-analysis to estimate the occurrence of insomnia in patients with solid cancer treated with immunotherapy using checkpoint inhibitors (CPI). METHODS: PubMed and ClinicalTrials.gov were searched for phase 3 studies in solid tumours where treatment included a checkpoint inhibitor in the experimental arm. Data on the incidence of insomnia were acquired from the adverse events tables available from clinicaltrials.gov and/or from the full texts. Random effect logistic model was used to compare pooled data. Heterogeneity between studies was assessed using Cochrane Q statistics and I2 statistics. RESULTS: A total of 54 studies (including six three-arm studies) involving 37,352 patients were included in the analysis. Insomnia was reported in 8.3% of subjects (95% confidence interval [CI] 8.0%-8.7%) treated with immunotherapy. Insomnia was significantly more common in patients receiving immunotherapy compared to those enrolled in study arms with inactive treatment (odds ratio [OR] 1.49, 95% CI 1.13-1.96). The odds for insomnia were similar between the arms for studies comparing CPI versus chemotherapy and CPI versus non-immunologic targeted therapies (OR 1.07, 95% CI 0.94-1.22 and OR 1.40, 95% CI 0.90-2.18, respectively). The OR for insomnia was higher for cytotoxic T-lymphocyte antigen 4 (CTLA-4) receptor inhibitors compared to the inhibitors of programmed death-1 (PD-1) receptor (OR 1.36, 95% CI 1.06 - 1.74). CONCLUSION: Cancer immunotherapy using CPI is associated with insomnia but the odds of developing the symptom are not greater with immunotherapy than with other systemic modalities including chemotherapy and non-immunologic targeted therapies.

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute and Faculty of Medicine Masaryk University Brno Czechia

Department of Oncology 1st Faculty of Medicine Charles University and Thomayer University Hospital Prague Czechia

Institute of Biostatistics and Analyses Masaryk University Brno Czechia

Zobrazit více v PubMed

Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol Off J Am Soc Clin Oncol (2001) 19:895–908. doi: 10.1200/JCO.2001.19.3.895 PubMed DOI

Sigurdardottir LG, Valdimarsdottir UA, Fall K, Rider JR, Lockley SW, Schernhammer E, et al. . Circadian disruption, sleep loss, and prostate cancer risk: A systematic review of epidemiologic studies. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol (2012) 21:1002–11. doi: 10.1158/1055-9965.EPI-12-0116 PubMed DOI PMC

Wendeu-Foyet MG, Menegaux F. Circadian disruption and prostate cancer risk: An updated review of epidemiological evidences. Cancer Epidemiol Biomarkers Prev Publ Am Assoc Cancer Res cosponsored by Am Soc Prev Oncol (2017) 26:985–91. doi: 10.1158/1055-9965.EPI-16-1030 PubMed DOI

Truong T, Liquet B, Menegaux F, Plancoulaine S, Laurent-Puig P, Mulot C, et al. . Breast cancer risk, nightwork, and circadian clock gene polymorphisms. Endocr Relat Cancer (2014) 21:629–38. doi: 10.1530/ERC-14-0121 PubMed DOI

Walker WH, 2nd, Borniger JC. Molecular mechanisms of cancer-induced sleep disruption. Int J Mol Sci (2019) 20. doi: 10.3390/ijms20112780 PubMed DOI PMC

Ranjbaran Z, Keefer L, Stepanski E, Farhadi A, Keshavarzian A. The relevance of sleep abnormalities to chronic inflammatory conditions. Inflammation Res Off J Eur Histamine Res Soc . (2007) 56:51–7. doi: 10.1007/s00011-006-6067-1 PubMed DOI

Dzierzewski JM, Donovan EK, Kay DB, Sannes TS, Bradbrook KE. Sleep inconsistency and markers of inflammation. Front Neurol (2020) 11:1042. doi: 10.3389/fneur.2020.01042 PubMed DOI PMC

Payne JK, Held J, Thorpe J, Shaw H. Effect of exercise on biomarkers, fatigue, sleep disturbances, and depressive symptoms in older women with breast cancer receiving hormonal therapy. Oncol Nurs Forum (2008) 35:635–42. doi: 10.1188/08.ONF.635-642 PubMed DOI

Barsevick A, Beck SL, Dudley WN, Wong B, Berger AM, Whitmer K, et al. . Efficacy of an intervention for fatigue and sleep disturbance during cancer chemotherapy. J Pain Symptom Manage (2010) 40:200–16. doi: 10.1016/j.jpainsymman.2009.12.020 PubMed DOI PMC

Sillah A, Peters U, Watson NF, Tykodi SS, Hall ET, Silverman A, et al. . Associating sleep problems with advanced cancer diagnosis, and immune checkpoint treatment outcomes: A pilot study. Support Care Cancer Off J Multinatl Assoc Support Care Cancer (2022) 30:3829–38. doi: 10.1007/s00520-022-06825-w PubMed DOI PMC

Cogdill AP, Andrews MC, Wargo JA. Hallmarks of response to immune checkpoint blockade. Br J Cancer (2017) 117:1–7. doi: 10.1038/bjc.2017.136 PubMed DOI PMC

Martins F, Sofiya L, Sykiotis GP, Lamine F, Maillard M, Fraga M, et al. . Adverse effects of immune-checkpoint inhibitors: Epidemiology, management and surveillance. Nat Rev Clin Oncol (2019) 16:563–80. doi: 10.1038/s41571-019-0218-0 PubMed DOI

Irwin MR, Olmstead R, Carroll JE. Sleep disturbance, sleep duration, and inflammation: A systematic review and meta-analysis of cohort studies and experimental sleep deprivation. Biol Psychiatry (2016) 80:40–52. doi: 10.1016/j.biopsych.2015.05.014 PubMed DOI PMC

Xia L, Zhang P, Niu J-W, Ge W, Chen J-T, Yang S, et al. . Relationships between a range of inflammatory biomarkers and subjective sleep quality in chronic insomnia patients: A clinical study. Nat Sci Sleep (2021) 13:1419–28. doi: 10.2147/NSS.S310698 PubMed DOI PMC

Kiss I, Kuhn M, Hrusak K, Buchler T. Incidence of fatigue associated with immune checkpoint inhibitors in patients with cancer: A meta-analysis. ESMO Open (2022) 7:100474. doi: 10.1016/j.esmoop.2022.100474 PubMed DOI PMC

Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, et al. . Association of sex, age, and Eastern cooperative oncology group performance status with survival benefit of cancer immunotherapy in randomized clinical trials: A systematic review and meta-analysis. JAMA Netw Open (2020) 3:e2012534. doi: 10.1001/jamanetworkopen.2020.12534 PubMed DOI PMC

Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, et al. . Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol (2019) 5:1008–19. doi: 10.1001/jamaoncol.2019.0393 PubMed DOI PMC

Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JPA, et al. . The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ (2009) 339:b2700. doi: 10.1136/bmj.b2700 PubMed DOI PMC

Tufanaru C, Munn Z, Stephenson M, Aromataris E. Fixed or random effects meta-analysis? common methodological issues in systematic reviews of effectiveness. Int J Evid Based Healthc (2015) 13:196–207. doi: 10.1097/XEB.0000000000000065 PubMed DOI

Rücker G, Cates CJ, Schwarzer G. Methods for including information from multi-arm trials in pairwise meta-analysis. Res Synth Methods (2017) 8:392–403. doi: 10.1002/jrsm.1259 PubMed DOI

Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. . GRADE guidelines: 3. Rating the quality of evidence. J Clin Epidemiol (2011) 64:401–6. doi: 10.1016/j.jclinepi.2010.07.015 PubMed DOI

Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (2003) 327:557–60. doi: 10.1136/bmj.327.7414.557 PubMed DOI PMC

Balduzzi S, Rücker G, Schwarzer G. How to perform a meta-analysis with r: A practical tutorial. Evid Based Ment Health (2019) 22:153–60. doi: 10.1136/ebmental-2019-300117 PubMed DOI PMC

Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. . Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711–23. doi: 10.1056/NEJMoa1003466 PubMed DOI PMC

Robert C, Thomas L, Bondarenko I, O’Day S, Weber J, Garbe C, et al. . Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517–26. doi: 10.1056/NEJMoa1104621 PubMed DOI

Reck M, Luft A, Szczesna A, Havel L, Kim S-W, Akerley W, et al. . Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol (2016) 34:3740–8. doi: 10.1200/JCO.2016.67.6601 PubMed DOI

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. . Durvalumab after chemoradiotherapy in stage III non-Small-Cell lung cancer. N Engl J Med (2017) 377:1919–29. doi: 10.1056/NEJMoa1709937 PubMed DOI

Beer TM, Kwon ED, Drake CG, Fizazi K, Logothetis C, Gravis G, et al. . Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol (2017) 35:40–7. doi: 10.1200/JCO.2016.69.1584 PubMed DOI

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. . Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med (2017) 376:1015–26. doi: 10.1056/NEJMoa1613683 PubMed DOI PMC

Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. . First-line nivolumab in stage IV or recurrent non-Small-Cell lung cancer. N Engl J Med (2017) 376:2415–26. doi: 10.1056/NEJMoa1613493 PubMed DOI PMC

Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, et al. . INfluenza vaccine indication during therapy with immune checkpoint inhibitors: A transversal challenge. INVIDIa study Immunotherapy (2018) 10:1229–39. doi: 10.2217/imt-2018-0080 PubMed DOI

Rittmeyer A, Barlesi F, Waterkamp D, Park K, Ciardiello F, von Pawel J, et al. . Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): A phase 3, open-label, multicentre randomised controlled trial. Lancet (London England) (2017) 389:255–65. doi: 10.1016/S0140-6736(16)32517-X PubMed DOI PMC

Socinski MA, Jotte RM, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N, et al. . Atezolizumab for first-line treatment of metastatic nonsquamous NSCLC. N Engl J Med (2018) 378:2288–301. doi: 10.1056/NEJMoa1716948 PubMed DOI

Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. . Pembrolizumab plus chemotherapy in metastatic non-Small-Cell lung cancer. N Engl J Med (2018) 378:2078–92. doi: 10.1056/NEJMoa1801005 PubMed DOI

Horn L, Mansfield AS, Szczęsna A, Havel L, Krzakowski M, Hochmair MJ, et al. . First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med (2018) 379:2220–9. doi: 10.1056/NEJMoa1809064 PubMed DOI

Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJM, et al. . Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): A multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol (2014) 15:700–12. doi: 10.1016/S1470-2045(14)70189-5 PubMed DOI PMC

Larkin J, Minor D, D’Angelo S, Neyns B, Smylie M, Miller WHJ, et al. . Overall survival in patients with advanced melanoma who received nivolumab versus investigator’s choice chemotherapy in CheckMate 037: A randomized, controlled, open-label phase III trial. J Clin Oncol Off J Am Soc Clin Oncol (2018) 36:383–90. doi: 10.1200/JCO.2016.71.8023 PubMed DOI PMC

Motzer RJ, Tannir NM, McDermott DF, Aren Frontera O, Melichar B, Choueiri TK, et al. . Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma. N Engl J Med (2018) 378:1277–90. doi: 10.1056/NEJMoa1712126 PubMed DOI PMC

Paz-Ares L, Luft A, Vicente D, Tafreshi A, Gümüş M, Mazières J, et al. . Pembrolizumab plus chemotherapy for squamous non-Small-Cell lung cancer. N Engl J Med (2018) 379:2040–51. doi: 10.1056/NEJMoa1810865 PubMed DOI

Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. . Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, phase 3 randomised controlled trial. Lancet (London England) (2018) 391:748–57. doi: 10.1016/S0140-6736(17)33297-X PubMed DOI

Shitara K, Özgüroğlu M, Bang Y-J, Di Bartolomeo M, Mandalà M, Ryu M-H, et al. . Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): A randomised, open-label, controlled, phase 3 trial. Lancet (London England) (2018) 392:123–33. doi: 10.1016/S0140-6736(18)31257-1 PubMed DOI

Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. . Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N Engl J Med (2018) 379:2108–21. doi: 10.1056/NEJMoa1809615 PubMed DOI

Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. . Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): A randomised, open-label, phase 3 study. Lancet (London England) (2019) 393:156–67. doi: 10.1016/S0140-6736(18)31999-8 PubMed DOI

Eng C, Kim TW, Bendell J, Argilés G, Tebbutt NC, Di Bartolomeo M, et al. . Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): A multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol (2019) 20:849–61. doi: 10.1016/S1470-2045(19)30027-0 PubMed DOI

Mok TSK, Wu Y-L, Kudaba I, Kowalski DM, Cho BC, Turna HZ, et al. . Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial. Lancet (London England) (2019) 393:1819–30. doi: 10.1016/S0140-6736(18)32409-7 PubMed DOI

Paz-Ares L, Ciuleanu T-E, Cobo M, Schenker M, Zurawski B, Menezes J, et al. . First-line nivolumab plus ipilimumab combined with two cycles of chemotherapy in patients with non-small-cell lung cancer (CheckMate 9LA): An international, randomised, open-label, phase 3 trial. Lancet Oncol (2021) 22:198–211. doi: 10.1016/S1470-2045(20)30641-0 PubMed DOI

Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. . Nivolumab versus docetaxel in advanced nonsquamous non-Small-Cell lung cancer. N Engl J Med (2015) 373:1627–39. doi: 10.1056/NEJMoa1507643 PubMed DOI PMC

Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, et al. . Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med (2019) 380(12):1116–27. doi: 10.1056/NEJMoa1816714 PubMed DOI

Rini BI, Powles T, Atkins MB, Escudier B, McDermott DF, Suarez C, et al. . Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial. Lancet (London England) (2019) 393:2404–15. doi: 10.1016/S0140-6736(19)30723-8 PubMed DOI

West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, et al. . Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): A multicentre, randomised, open-label, phase 3 tri. Lancet Oncol (2019) 20:924–37. doi: 10.1016/S1470-2045(19)30167-6 PubMed DOI

Ferris RL, Haddad R, Even C, Tahara M, Dvorkin M, Ciuleanu TE, et al. . Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study. Ann Oncol Off J Eur Soc Med Oncol (2020) 31:942–50. doi: 10.1016/j.annonc.2020.04.001 PubMed DOI

Gutzmer R, Stroyakovskiy D, Gogas H, Robert C, Lewis K, Protsenko S, et al. . Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAF(V600) mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London England) (2020) 395:1835–44. doi: 10.1016/S0140-6736(20)30934-X PubMed DOI

Herbst RS, Giaccone G, de Marinis F, Reinmuth N, Vergnenegre A, Barrios CH, et al. . Atezolizumab for first-line treatment of PD-L1-Selected patients with NSCLC. N Engl J Med (2020) 383:1328–39. doi: 10.1056/NEJMoa1917346 PubMed DOI

Jotte R, Cappuzzo F, Vynnychenko I, Stroyakovskiy D, Rodríguez-Abreu D, Hussein M, et al. . Atezolizumab in combination with carboplatin and nab-paclitaxel in advanced squamous NSCLC (IMpower131): Results from a randomized phase III trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2020) 15:1351–60. doi: 10.1016/j.jtho.2020.03.028 PubMed DOI

Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, et al. . Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol Off J Am Soc Clin Oncol (2020) 38:4138–48. doi: 10.1200/JCO.20.01888 PubMed DOI

Mittendorf EA, Zhang H, Barrios CH, Saji S, Jung KH, Hegg R, et al. . Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 tri. Lancet (London England) (2020) 396:1090–100. doi: 10.1016/S0140-6736(20)31953-X PubMed DOI

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, et al. . Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): A randomised, open-label, multicentre, phase 3 trial. Lancet Oncol (2020) 21:1574–88. doi: 10.1016/S1470-2045(20)30541-6 PubMed DOI

Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WEE, Poddubskaya E, et al. . Nivolumab versus docetaxel in advanced squamous-cell non-Small-Cell lung cancer. N Engl J Med (2015) 373:123–35. doi: 10.1056/NEJMoa1504627 PubMed DOI PMC

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, et al. . Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med (2020) 383:1218–30. doi: 10.1056/NEJMoa2002788 PubMed DOI

Rizvi NA, Cho BC, Reinmuth N, Lee KH, Luft A, Ahn M-J, et al. . Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: The MYSTIC phase 3 randomized clinical trial. JAMA Oncol (2020) 6:661–74. doi: 10.1001/jamaoncol.2020.0237 PubMed DOI PMC

Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. . Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: Randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol Off J Am Soc Clin Oncol (2020) 38:2369–79. doi: 10.1200/JCO.20.00793 PubMed DOI PMC

Baas P, Scherpereel A, Nowak AK, Fujimoto N, Peters S, Tsao AS, et al. . First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): A multicentre, randomised, open-label, phase 3 trial. Lancet (London England) (2021) 397:375–86. doi: 10.1016/S0140-6736(20)32714-8 PubMed DOI

Motzer R, Alekseev B, Rha S-Y, Porta C, Eto M, Powles T, et al. . Lenvatinib plus pembrolizumab or everolimus for advanced renal cell carcinoma. N Engl J Med (2021) 384:1289–300. doi: 10.1056/NEJMoa2035716 PubMed DOI

Owonikoko TK, Park K, Govindan R, Ready N, Reck M, Peters S, et al. . Nivolumab and ipilimumab as maintenance therapy in extensive-disease small-cell lung cancer: CheckMate 451. J Clin Oncol Off J Am Soc Clin Oncol (2021) 39:1349–59. doi: 10.1200/JCO.20.02212 PubMed DOI PMC

Powles T, Csőszi T, Özgüroğlu M, Matsubara N, Géczi L, Cheng SY-S, et al. . Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): A randomised, open-label, phase 3 trial. Lancet Oncol (2021) 22:931–45. doi: 10.1016/S1470-2045(21)00152-2 PubMed DOI

Winer EP, Lipatov O, Im S-A, Goncalves A, Muñoz-Couselo E, Lee KS, et al. . Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): A randomised, open-label, phase 3 trial. Lancet Oncol (2021) 22:499–511. doi: 10.1016/S1470-2045(20)30754-3 PubMed DOI

Khorana AA, Soff GA, Kakkar AK, Vadhan-Raj S, Riess H, Wun T, et al. . Rivaroxaban for thromboprophylaxis in high-risk ambulatory patients with cancer. N Engl J Med (2019) 380:720–8. doi: 10.1056/NEJMoa1814630 PubMed DOI

Wu Y-L, Lu S, Cheng Y, Zhou C, Wang J, Mok T, et al. . Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol Off Publ Int Assoc Study Lung Cancer (2019) 14:867–75. doi: 10.1016/j.jtho.2019.01.006 PubMed DOI

Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, et al. . Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med (2015) 373:1803–13. doi: 10.1056/NEJMoa1510665 PubMed DOI PMC

Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro GJ, et al. . Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet (London England) (2019) 394:1915–28. doi: 10.1016/S0140-6736(19)32591-7 PubMed DOI

Finn RS, Ryoo B-Y, Merle P, Kudo M, Bouattour M, Lim HY, et al. . Pembrolizumab as second-line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE-240: A randomized, double-blind, phase III trial. J Clin Oncol Off J Am Soc Clin Oncol (2020) 38:193–202. doi: 10.1200/JCO.19.01307 PubMed DOI

Barlesi F, Vansteenkiste J, Spigel D, Ishii H, Garassino M, de Marinis F, et al. . Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN lung 200): An open-label, randomised, phase 3 study. Lancet Oncol (2018) 19:1468–79. doi: 10.1016/S1470-2045(18)30673-9 PubMed DOI

Paz-Ares L, Dvorkin M, Chen Y, Reinmuth N, Hotta K, Trukhin D, et al. . Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): A randomised, controlled, open-label, phase 3 trial. Lancet (London England) (2019) 394:1929–39. doi: 10.1016/S0140-6736(19)32222-6 PubMed DOI

Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. . Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. N Engl J Med (2016) 375:1845–55. doi: 10.1056/NEJMoa1611299 PubMed DOI PMC

Ferris RL, Blumenschein GJ, Fayette J, Guigay J, Colevas AD, Licitra L, et al. . Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med (2016) 375:1856–67. doi: 10.1056/NEJMoa1602252 PubMed DOI PMC

Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): A randomised controlled trial. Lancet (London England) (2016) 387:1540–50. doi: 10.1016/S0140-6736(15)01281-7 PubMed DOI

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. . Pembrolizumab versus chemotherapy for PD-L1-Positive non-Small-Cell lung cancer. N Engl J Med (2016) 375:1823–33. doi: 10.1056/NEJMoa1606774 PubMed DOI

US Department of Health and Human Services. National Institutes of Health. National Cancer Institute . Common Terminology Criteria for Adverse Events (CTCAE) Version 5. (2017). Available at: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_reference_5x7.pdf [Accessed May 01, 2022]

Govindan R, Szczesna A, Ahn M-J, Schneider C-P, Gonzalez Mella PF, Barlesi F, et al. . Phase III trial of ipilimumab combined with paclitaxel and carboplatin in advanced squamous non-Small-Cell lung cancer. J Clin Oncol (2017) 35:34493457. doi: 10.1200/JCO.2016.71.7629 PubMed DOI

Maio M, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, et al. . Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. Lancet Oncol (2017) 18:12611273. doi: 10.1016/S1470-2045(17)30446-1 PubMed DOI

Yang T, Yang Y, Wang D, Li C, Qu Y, Guo J, et al. . The clinical value of cytokines in chronic fatigue syndrome. J Transl Med (2019) 17:213. doi: 10.1186/s12967-019-1948-6 PubMed DOI PMC

Dimitriou F, Hogan S, Menzies AM, Dummer R, Long GV. Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy. Eur J Cancer (2021) 157:214–24. doi: 10.1016/j.ejca.2021.08.031 PubMed DOI

Stroud CR, Hegde A, Cherry C, Naqash AR, Sharma N, Addepalli S, et al. . Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. J Oncol Pharm Pract Off Publ Int Soc Oncol Pharm Pract (2019) 25:551–7. doi: 10.1177/1078155217745144 PubMed DOI

Tarhini AA, Zahoor H, Lin Y, Malhotra U, Sander C, Butterfield LH, et al. . Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma. J Immunother Cancer (2015) 3:39. doi: 10.1186/s40425-015-0081-1 PubMed DOI PMC

Esfahani K, Miller WHJ. Reversal of autoimmune toxicity and loss of tumor response by interleukin-17 blockade. N Engl J Med (2017) 376:1989–91. doi: 10.1056/NEJMc1703047 PubMed DOI

van Leeuwen WMA, Lehto M, Karisola P, Lindholm H, Luukkonen R, Sallinen M, et al. . Sleep restriction increases the risk of developing cardiovascular diseases by augmenting proinflammatory responses through IL-17 and CRP. PloS One (2009) 4:e4589. doi: 10.1371/journal.pone.0004589 PubMed DOI PMC

Vgontzas AN, Zoumakis M, Papanicolaou DA, Bixler EO, Prolo P, Lin H-M, et al. . Chronic insomnia is associated with a shift of interleukin-6 and tumor necrosis factor secretion from nighttime to daytime. Metabolism (2002) 51:887–92. doi: 10.1053/meta.2002.33357 PubMed DOI

Hong H-K, Maury E, Ramsey KM, Perelis M, Marcheva B, Omura C, et al. . Requirement for NF-κB in maintenance of molecular and behavioral circadian rhythms in mice. Genes Dev (2018) 32:1367–79. doi: 10.1101/gad.319228.118 PubMed DOI PMC

Zhang Z, Zeng P, Gao W, Zhou Q, Feng T, Tian X. Circadian clock: A regulator of the immunity in cancer. Cell Commun Signal (2021) 19:37. doi: 10.1186/s12964-021-00721-2 PubMed DOI PMC

Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW. Inflammation and behavioral symptoms after breast cancer treatment: Do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol Off J Am Soc Clin Oncol (2011) 29:3517–22. doi: 10.1200/JCO.2011.36.1154 PubMed DOI PMC

Kornum BR. Narcolepsy type I as an autoimmune disorder. Handb Clin Neurol (2021) 181:161–72. doi: 10.1016/B978-0-12-820683-6.00012-9 PubMed DOI

Natori Y, Sasaki E, Soeda S, Furukawa S, Azami Y, Tokuda E, et al. . Risk of immunotherapy-related narcolepsy in genetically predisposed patients: A case report of narcolepsy after administration of pembrolizumab. J Immunother Cancer (2020) 8. doi: 10.1136/jitc-2020-001164 PubMed DOI PMC

Malone M, Harris AL, Luscombe DK. Assessment of the impact of cancer on work, recreation, home management and sleep using a general health status measure. J R Soc Med (1994) 87:386–9. PubMed PMC

Berger AM, Parker KP, Young-McCaughan S, Mallory GA, Barsevick AM, Beck SL, et al. . Sleep wake disturbances in people with cancer and their caregivers: state of the science. Oncol Nurs Forum (2005) 32:E98–126. doi: 10.1188/05.ONF.E98-E126 PubMed DOI

Ashraf S, Jafri MAS, Alsharedi MF. Insomnia in cancer patients. J Clin Oncol (2021) 39:e18651–1. doi: 10.1200/JCO.2021.39.15_suppl.e18651 DOI

Edition F. Diagnostic and statistical manual of mental disorders. Am Psychiatr Assoc (2013) 21:591–643.

Griewing LM, Schweizer C, Schubert P, Rutzner S, Eckstein M, Frey B, et al. . Questionnaire-based detection of immune-related adverse events in cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. BMC Cancer (2021) 21:314. doi: 10.1186/s12885-021-08006-0 PubMed DOI PMC

Chellappa SL, Morris CJ, Scheer FAJL. Effects of circadian misalignment on cognition in chronic shift workers. Sci Rep (2019) 9:699. doi: 10.1038/s41598-018-36762-w PubMed DOI PMC

Joly F, Castel H, Tron L, Lange M, Vardy J. Potential effect of immunotherapy agents on cognitive function in cancer patients. J Natl Cancer Inst (2020) 112:123–7. doi: 10.1093/jnci/djz168 PubMed DOI PMC